Evidence map›Paper›PMID 32848857›Full record

ReviewFrontiers in physiology2020

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction.

Xiaodong Peng, Linling Li, Mengxia Zhang, Qianqian Zhao, Kui Wu, Rong Bai, Yanfei Ruan, Nian Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Dapagliflozin for Atrial Fibrillation.Cardiovascular drugs and therapy · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaodong PengDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Linling LiDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Mengxia ZhangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Qianqian ZhaoDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Kui WuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Rong BaiDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yanfei RuanDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Nian LiuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Anzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering agents that significantly improve the prognosis of patients with type 2 diabetes (T2D) and heart failure. SGLT2i has recently been implicated in the treatment of atrial fibrillation (AF) with clinical data demonstrating that these agents decrease the incidence of AF events in patients with T2D. Fundamental findings have suggested that SGLT2i may alleviate atrial electrical and structural remodeling. The underlying mechanisms of SGLT2i are likely associated with balancing the sodium and calcium handling disorders and mitigating the mitochondrial dysfunction in atrial myocytes. This review illustrates the advances in understanding the underlying mechanisms of SGLT2i as an evolving treatment modality for AF.

Indexed as

atrial fibrillationcalcium handlingmitochondriasodium-glucose cotransporter 2 inhibitorssodium-hydrogen exchanger isoform 1

Identifiers

PMID32848857
PMCPMC7417344
OpenAlexW3047122516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.